Beigene Ltd.

6 trials Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

0 Recruiting

6 Completed trials

7 Countries active

7 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I

Phase I (FiH)

Phase III: 1 Phase II: 1 Phase I: 3 Phase I (FiH): 1

Oversight events:

3 temporary halts across 2 trials

View oversight register →

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 3 Renal cell carcinoma 3 Squamous cell carcinoma of head and neck 3 Small cell lung cancer 2 Triple negative breast cancer 2 Hormone receptor positive HER2 negative breast cancer 1 Adenocarcinoma gastric 1 Ductal adenocarcinoma of pancreas 1 Hormone receptor positive breast cancer 1 Mismatch repair cancer syndrome 1 DNA mismatch repair protein gene mutation 1 Mesothelioma 1

Top IMPs

TISLELIZUMAB 2 LBL-007 1 OCIPERLIMAB 1 PEMBROLIZUMAB 1 SURZEBICLIMAB 1 ZANUBRUTINIB 1

All trials

6 total

A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DG… Ended

2023-503996-38-00 Phase I 1 country
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3… Ended

2023-505322-34-00 Phase I 1 country
Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors Ended

2022-500694-14-00 Phase I (FiH) 4 countries LBL-007; SURZEBICLIMAB; TISLELIZUMAB
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab… Ended

2023-507317-10-00 Phase III 6 countries OCIPERLIMAB; PEMBROLIZUMAB; TISLELIZUMAB
A Phase 2 Study combining BGB-3111 with Obinutuzumab compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma Ended

2023-509975-17-00 Phase II 5 countries ZANUBRUTINIB
A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies Ended

2025-521600-21-00 Phase I 2 countries

Showing 1–6 of 6 trials

← All sponsors A–Z